Zhao Yan New Medicine: Shareholders Gu Xiaolei and Gu Meifang plan to reduce their holdings by 2.01% and 0.99% respectively.

Zhao Yanxin Pharmaceuticals announced that shareholders Gu Xiaolei and Gu Meifang will adjust their reduction plan. They will now not sell more than 30,742,500 shares, accounting for 4.1026% of the company's total shares, through centralized bidding. Instead, they will sell no more than 3.00% of the company's total shares within three months from the date of this announcement after the completion of three trading days. Gu Xiaolei plans to sell a maximum of 5,020,600 shares through centralized bidding and 10,041,200 shares through block trading, totaling no more than 15,061,800 shares, accounting for 2.01%. Gu Meifang plans to sell a maximum of 2,472,800 shares through centralized bidding and 4,945,600 shares through block trading, totaling no more than 7,418,400 shares, accounting for 0.99%. The reduction period is from March 20, 2026, to June 19, 2026.